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Rosacea is a chronic inflammatory skin disorder. Inflammation and oxidative stress are
involved in the etiopathogenesis of rosacea and chronic kidney disease (CKD). This study
aimed to investigate the association between rosacea and CKD.
Methods
This population-based cohort study identified 277 patients with rosacea in the Taiwan
National Health Insurance Research Database during 2001–2005. These patients were
matched for age, sex, and comorbidities with 2216 patients without rosacea. All subjects
were individually followed-up for 8–12 years to identify those who subsequently developed
CKD
Results
The incidence rates of CKD per 1000 person-years were 16.02 in patients with rosacea and
10.63 in the non-rosacea reference population. After adjusting for other covariates and con-
sidering the competing risk of mortality, patients with rosacea remained at increased risk of
CKD (adjusted sub-distribution hazard ratio (aSD-HR) 2.00; 95% confidence interval (CI)
1.05–3.82). The aSD-HRs (95% CI) for CKD were 1.82 (0.83–4.00) and 2.53 (1.11–5.75) for
patients with mild and moderate-to-severe rosacea, respectively.
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Conclusions
Rosacea is an independent risk factor for CKD. High rosacea severity and old age further
increased CKD risk in patients with rosacea. Careful monitoring for CKD development
should be included as part of integrated care for patients with rosacea.
Introduction
Rosacea is a chronic inflammatory cutaneous disorder characterized by centrofacial erythema,
telangiectasias, papules, and pustules. Aberrations in immune response and dysregulation of
the neurovascular system are presumed to be key pathophysiologic components of the disease.
[1, 2] Recent studies suggest that rosacea is a systemic disorder and not merely a skin condi-
tion. Prior studies reported that it is associated with dyslipidemia, hypertension, metabolic dis-
eases, alcohol consumption, tobacco smoking, cardiovascular diseases, and gastroesophageal
reflux disease,[3–5] all of which are also prevalent in patients with chronic kidney disease
(CKD).[6–8]
Accumulating evidence suggests that rosacea pathogenesis is linked to overexpression of
pro-inflammatory cytokines and higher reactive oxygen species production.[9–11] Similarly,
previous studies reported that chronic low-grade inflammation and oxidative stress are impor-
tant in CKD development.[12, 13] Because rosacea and CKD share some pathogenic mecha-
nisms and associated conditions, it is tempting to posit an association between these diseases.
Patients with inflammatory conditions such as psoriasis and rheumatoid arthritis have a high
risk of CKD.[14–16] Like that of psoriasis, the underlying mechanism of rosacea is thought to
be associated with inflammatory cascades.[17, 18] However, the relationship between rosacea
and CKD has not been previously investigated. We therefore assessed the risk of CKD in a
large, nationally representative, population-based cohort of Chinese patients with rosacea in
Taiwan.
Materials and methods
Study design and data source
The data used in this cohort study were obtained from the Longitudinal National Health
Insurance Research Database (LHID) 2000, which is a subset of the National Health Insurance
Research Database (NHIRD). The NHIRD is derived from the Taiwanese National Health
Insurance (NHI) program, which was launched in 1995 to finance health care for all citizens.
For the LHID2000, about 1,000,000 representative individuals were randomly sampled from
the NHI Registry of Beneficiaries in 2000. The database includes information on inpatient
care, outpatient care, ambulatory care, and prescription drugs for the period from January 1,
1996 through December 31, 2013. And patient diagnoses were coded using the International
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). The Taiwanese
NHI program provides care for approximately 99% of the Taiwanese population of more than
23 million people and offers unique possibilities for research. To ensure the accuracy and reli-
ability of coding, the Bureau of the NHI of Taiwan performs random cross-checking, requests
justifications by invited physicians, imposes heavy fines for false claims and overcharging, and
initiates malpractice proceedings for fraudulent claims. Thus, the NHIRD is generally regarded
as accurate and reliable. Confidentiality assurances were addressed by abiding by the data reg-
ulations of the NHI Bureau, and a formal written waiver for ethical approval was obtained
from the local investigational research bureau of the National Taiwan University Hospital
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Hsin-Chu Branch, Hsin-Chu, Taiwan (103-024-E). All patient records and information were
anonymized and de-identified before the analysis.
Study population
This retrospective cohort study analyzed data from individuals who received a new diagnosis
of rosacea (ICD-9-CM code 695.3) during ambulatory visits or inpatient care episodes between
January 1, 2001 and December 31, 2005. To ensure diagnostic validity, we required that pa-
tients have at least 2 dermatologist diagnoses. Because acne (ICD-9-CM code 706.1), sebor-
rheic dermatitis (ICD-9-CM code 690.1), and cutaneous lupus erythematosus (ICD-9-CM
code 695.4) are frequently confused with rosacea, patients with 2 diagnoses of any of these dis-
eases were excluded from the study group. The initial diagnosis date was defined as the index
date of entry into the rosacea cohort.
Propensity score matching adjusted for sex, age, and comorbidities was used to assemble a
comparison group among subjects without rosacea and CKD in the LHID2000. Each individ-
ual with rosacea was paired with 8 individuals without rosacea on the index enrollment date.
The matched comorbidities included hypertension (ICD-9-CM codes 401–402), diabetes mel-
litus (ICD-9-CM 250.xx), dyslipidemia (ICD 9-CM code 272.x), and cardiovascular disease
(ICD-9-CM 410–429). Patients in the study cohort and control cohort were excluded if they
were younger than 18 years or had CKD or rosacea before the index date (Fig 1). Patients with
rosacea were stratified by disease severity as having moderate-to-severe or mild rosacea.
Patients who received oral drugs (including doxycycline, minocycline, tetracycline, metronida-
zole, and isotretinoin) for rosacea at least 3 times during the first year of follow-up were con-
sidered to have moderate-to-severe rosacea. The remaining patients were considered to have
mild rosacea.
Outcome
The primary outcome was defined as the first ambulatory visit, hospitalization, or surgical pro-
cedure for CKD (ICD-9-CM codes: 580–589, 753, 403, 404, 250.4, 274.1, 440.1, 442.1, 447.3,
572.4, 642.1, 646.2). To investigate the risk of developing CKD during the follow-up period, all
individuals in the study and comparison cohorts were tracked for 8–12 years from their index
enrollment date until death or the end of the study period.
Statistical analysis
Frequencies and percentages are used to present descriptive statistics of the study sample. The
chi-square test was used to compare distributions of baseline demographic characteristics and
selected comorbidities between patients with and without rosacea. Cox proportional hazards
regression was used to estimate the effect of rosacea on CKD. Covariates adjusted in multivari-
able Cox regression analysis included gender, age, diabetes, hypertension, hyperlipidemia, car-
diovascular disease, systemic lupus erythematosus, rheumatoid arthritis, polycystic kidney
disease, medications putatively associated with CKD risk (non-steroidal anti-inflammatory
drugs, angiotensin-converting-enzyme inhibitors/angiotensin II receptor antagonists, loop
diuretics, and statin), Charlson comorbidity index score, and annual ambulatory care visits, as
detailed in previous studies.[19] The Kaplan–Meier method and log-rank test were used to
compare cumulative incidences of CKD between patients with and without rosacea. CKD inci-
dences in the rosacea and control cohorts were calculated by dividing the number of patients
with CKD by the total number of person-years. Death before CKD incidence was considered
as a competing risk event. In addition, Cox proportional hazard models with competing risk
analysis were used to estimate CKD risk among rosacea patients, as described previously.[20]
CKD risk in patients with rosacea
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Fig 1. Selection of study population. CKD, chronic kidney disease; LHID, Longitudinal National Health Insurance Research Database;
NHIRD, National Health Insurance Research Database.
https://doi.org/10.1371/journal.pone.0180446.g001
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Analyses were performed with SAS v9.3 (SAS Institute, Cary, NC). A P value of<0.05 was con-
sidered to indicate statistical significance.
Results
The study comprised 277 patients with rosacea and 2216 age-, sex-, and comorbidity-matched
reference subjects. Table 1 shows the sociodemographic characteristics of the patients. After
propensity score matching, no significant differences in sex, age, or comorbidities were noted
between patients with and without rosacea. Approximately 71% of patients were women and
29% were men in both the study and control groups. Most study participants were aged 30–49
years.
The median interval to CKD was 9.92 years, and there was no significant different between
rosacea patients (median 9.80 years; interquartile range (IQR): 8.68–11.34) and controls
Table 1. Background characteristics and comorbidities of patients with and without rosacea.
Characteristic No.(%) of individuals p-value
Patients with rosacea N = 277 Patients without rosacea N = 2216
Sex
Female 196(70.76) 1570(70.85) 0.9751
Male 81(29.24) 646(29.15)
Age Group






Diabetes 1(0.6) 8(0.36) 1.0000
Hypertension 13(4.69) 105(4.74) 0.9734
Hyperlipidemia 7(2.53) 56(2.53) 1.0000
Cardiovascular diseases 8(2.89) 52(2.35) 0.5793
Systemic lupus erythematosus 2(0.72) 2(0.09) 0.0634
Rheumatoid arthritis 2(0.72) 7(0.32) 0.2204
Polycystic kidney disease 0(0.0) 0(0.0) _
Charlson comorbidity index
0 243(87.73) 2018(91.06) 0.0512
1 28(10.11) 139(6.27)
≧2 6(2.17) 59(2.66)
Drug use 107(38.63) 906(40.88) 0.4710
Loop diuretics 1(0.36) 26(1.17) 0.3537
Statin 2(0.72) 23(1.04) 1.0000
NSAID 103(37.18) 877(39.58) 0.4423
ACEI 0(0.00) 10(0.45) 0.6144
ARB 6(2.17) 28(1.26) 0.2630
Annual ambulatory care visits† 19(10–29) 12(6–21) <0.0001
<15 117(42.24) 1366(61.64) <0.0001*
≧15 160(57.76) 850(38.36)
* p<0.05 for comparison between patients with versus without rosacea.
†The overall OPD times: Median (Q1-Q3) = 15(6–23) months.
https://doi.org/10.1371/journal.pone.0180446.t001
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(median 9.95; IQR: 8.91–11.42). The overall CKD incidence rate was higher in patients with
rosacea than in the controls (16.02 vs. 10.63 per 1000 person-years, respectively). The Kaplan–
Meier curves for the cumulative CKD incidence rate in patients with and without rosacea are
shown in Fig 2. CKD development was 50% more likely in patients with rosacea (hazard ratio
(HR) 1.51; 95% confidence interval (CI) 1.08–2.09) than in those without rosacea, and this
association remained significant after adjusting for other covariates (adjusted HR 1.40; 95%
CI 1.01–1.96). The Cox proportional hazard models with competing risk analysis yielded simi-
lar results (adjusted subdistribution (SD)-HR 2.00; 95% CI 1.05–3.82). When patients were
stratified by age group, the increase in CKD risk was highest for patients aged 30–39 years.
However, in the competing risk model the association between rosacea and CKD was not sig-
nificant for patients aged 30–39 years. Patients older than 50 years had a significant risk of
CKD (adjusted SD-HR for age 50–59 years, 3.68; 95% CI 1.00–13.56; adjusted SD-HR for 60
+ years, 4.24; 95% CI 1.63–11.04) (Table 2).
When patients with rosacea were further categorized as those with moderate-to-severe
rosacea (n = 203 (73.3%)) and those with mild rosacea (n = 74 (26.7%)). Patients with moder-
ate-to-severe rosacea had a higher HR for CKD than those with mild rosacea. After adjustment
for all other covariates and considering the competing risk of mortality, only those with mod-
erate-to-severe rosacea had a significantly higher HR for CKD as compared with the non-rosa-
cea controls. (SD-HR 2.53; 95% CI 1.11–5.75; P = 0.026) (Table 3).
Discussion
Rosacea has long been considered a disease limited to the skin, but an increasing number of
studies have observed an association between rosacea and extracutaneous diseases, which sug-
gests it has far-reaching systemic effects. A recent study compared cardiovascular disease
(CVD) risk factors among 60 rosacea patients and 50 age- and sex-matched controls and
found that patients with rosacea were more likely than controls to have higher levels of total
cholesterol (199 vs. 163 mg/dL, P< 0.001), low-density lipoprotein cholesterol (121 vs. 101
Fig 2. Kaplan–Meier curves. Cumulative incidence rate of CKD in patients with and without rosacea.
https://doi.org/10.1371/journal.pone.0180446.g002
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mg/dL, P = 0.002), and C-reactive protein (0.43 vs. 0.24 mg/L, P = 0.007) and a family history
of premature CVD (P = 0.002).[3] Similarly, subsequent studies reported higher prevalences of
insulin resistance and CVD risk factors (elevated fasting blood glucose, total cholesterol, and
systolic and diastolic blood pressures, P< 0.05) in patients with rosacea.[4, 5, 21] Moreover,
Rainer et al. suggested that rosacea is associated with increased risk of CVD,[5] and a very
recent population-based study reported a significant association between rosacea and coronary
artery disease.[4] These associations between rosacea and certain comorbidities do not appear
to be attributable solely to shared CVD risk factors. Prior studies showed that the associations
of rosacea with some comorbidities did not substantially change after adjustment for tradi-
tional CVD risk factors [4, 5, 22] and that the strength of the associations increased in relation
Table 3. Hazard ratios for chronic kidney disease (CKD) by rosacea severity.









Patients without rosacea 2216 229
(10.33)
Ref. Ref. Ref. Ref.













1.59(0.91–2.81) 0.1066 2.61(0.94–7.21) 2.53(1.11–5.75) 0.0266*
HR, hazard ratio; CI, confidence interval; CKD, chronic kidney disease; Ref., reference group; SD-HR, sub-distribution hazard ratio.
a. Adjusted by the variables included in Table 1.
b. SD-HR was estimated from the competing risk model.
¶Rosacea patients who did not receive oral medications for the disease
†Rosacea patients who received oral medications for the disease, including doxycycline, minocycline, tetracycline, metronidazole, and isotretinoin
*P-value<0.05.
https://doi.org/10.1371/journal.pone.0180446.t003
Table 2. Incidences and hazard ratios for chronic kidney disease (CKD) in patients with and without rosacea.










CKD PRa Rate CKD PRa Rate
All
patients




Female 26 1889.54 13.76 151 15383.86 9.82 1.40(0.92–2.13) 1.41(0.93–2.15) 1.05(0.32–3.47) 1.20(0.35–4.04)
Male 16 732.55 21.84 78 6165.32 12.65 1.71(1.00–2.93) 1.41(0.81–2.47) 3.23(1.56–6.68)* 2.83(1.33–6.06)*
Age
18–29 4 470.35 8.50 20 3734.02 5.36 1.63(0.56–4.77) 1.42(0.46–4.37) — —
30–39 5 482.11 10.37 12 4196.11 2.86 3.63(1.28–
10.31)*
3.18(1.08–9.39)* 1.62(0.19–13.81) 1.22(0.21–7.18)
40–49 13 1081.54 12.02 70 8513.67 8.22 1.47(0.82–2.66) 1.47(0.80–2.67) 0.46(0.06–3.49) 0.72(0.08-.6.33)
50–59 10 360.72 27.72 59 3154.54 18.70 1.49(0.76–2.91) 1.41(0.71–2.81) 5.34(1.79–15.92)* 3.68(1.00–13.56)*
60+ 10 227.38 43.98 68 1950.84 34.86 1.27(0.65–2.47) 1.18(0.60–2.32) 3.31(1.32–8.32)* 4.24(1.63–11.04)*
*P < 0.05.
a. per 1000 person years
b. Adjusted by the variables included in Table 1.
c. SD-HR was estimated from the competing risk model, and there is no subject death in aged at 18~29.
HR, hazard ratio; CI, confidence interval; CKD, chronic kidney disease; PY, person-years; SD-HR, sub-distribution hazard ratio.
https://doi.org/10.1371/journal.pone.0180446.t002
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to rosacea severity.[5, 22] These findings suggest that other factors intrinsically linked to rosa-
cea contribute to the development of these comorbidities. Our study provided some support
for the hypothesis. Most of the abovementioned CVD risk factors are shared by rosacea and
CKD.[23] Nevertheless, using a propensity score matched-pair procedure and multivariable
Cox proportional hazards models, we found that rosacea was significantly associated with
CKD, even after adjusting for the effects of comorbidities.
Because of its increasing incidence and prevalence and progression to end-stage renal dis-
ease, CKD is a global public health burden. CKD limits longevity and increases costs to health-
care systems worldwide.[24] Moreover, as compared with the general population, patients
with inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, Sjo¨g-
ren syndrome, systemic scleroderma, and psoriatic disease are more likely to have CKD.[14–
16, 25] Accumulating evidence indicates that chronic low-grade inflammation resulting in
endothelial injury, impaired vasodilation, and glomerulosclerosis plays a major role in CKD
development and that various inflammatory cytokines are related to CKD pathogenesis and
progression.[12, 26–28] Rosacea is a common chronic inflammatory skin condition character-
ized by dysfunction in the innate and/or adaptive immune response. Pro-inflammatory cyto-
kines such as interleukin (IL)-1 β, IL-6, IL-8, and tumor necrosis factor-α are involved in
rosacea pathogenesis, and inflammasome-related genes (CASP-1 and NALP-3) are overex-
pressed in skin samples from rosacea patients. [9, 10, 29] These inflammatory mediators may
have an important role in CKD development.[27, 30–32] Consistent with these past studies,
our data indicate that patients with moderate-to-severe rosacea, who might have a greater
inflammation burden, had a higher risk of developing CKD than did patients with mild rosa-
cea. The result lends support to the hypothesis that inflammatory mediators are involved in
CKD pathogenesis and progression in patients with rosacea.
Previous studies of rosacea patients reported that the activity of paraoxone-1, an antioxi-
dant enzyme, was decreased and that oxidative stress was increased.[33] In addition, there was
a significant positive correlation between the magnitude of the reduction in cutaneous anti-
oxidant capacity and rosacea severity, indicating that oxidative stress may have a role in the
pathophysiology of rosacea.[33, 34] Similarly, evidence from numerous clinical studies con-
firms the importance of oxidative stress in CKD, as it can trigger the inflammatory process
and accelerate progression of renal injury.[13, 35] Although the evidence is not conclusive,
mechanisms involving inflammatory pathways and oxidative stress appear to contribute to the
association between rosacea and CKD risk.
The present competing risk model showed a significant association between rosacea and
CKD for patients older than 50 years, and CKD risk was highest among adults older than 60
years. A possible explanation for these findings is that age-associated decline in kidney func-
tion and loss of renal functional reserve in elderly adults increases the effects of rosacea-
induced inflammation and oxidative stress on CKD development. Nevertheless, more research
is needed in order to confirm this hypothesis.
Although this study was based on a large, high-quality, nationwide, population-based data-
base, several limitations must be considered. First, diagnosis of rosacea was based on second-
ary claims data, and misclassification is thus possible. To minimize this bias, the presence of
disease was defined as at least 2 ICD-9-CM diagnoses made by a relevant specialist. Moreover,
the reliability and validity of using claims data to identify patients with rosacea and CKD have
been demonstrated in previous epidemiologic studies.[4, 14–16, 36–38] This study relied on
ICD diagnoses for identification of rosacea and CKD. It is likely that some asymptomatic
patients did not seek medical treatment and therefore were not captured by this study design.
Some misclassification of patients with acute kidney injury or without CKD may have oc-
curred in the rosacea and control groups. However, this misclassification would have occurred
CKD risk in patients with rosacea
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in both the rosacea and control groups, would thus be nondifferential, and would bias effect
estimates toward the null. Second, the fact that hospital visits are more frequent for patients
with rosacea than for the general population may result in potential surveillance bias. How-
ever, laboratory testing of serum creatinine concentration and urine analysis, which are
required for CKD diagnosis, were not routinely performed during therapeutic monitoring of
rosacea. Moreover, the present results remained robust after adjustment for number of doctor
visits in both groups. Third, the NHIRD did not include information on rosacea subtypes, life-
style factors, or laboratory findings. Thus, we were unable to estimate glomerular filtration
rate or detect proteinuria at baseline and could not adjust for these unmeasured potential con-
founders. Fourth, we used treatment with systemic therapies as a surrogate marker for severe
disease. Doxycycline, minocycline, and tetracycline are also used to treat acne vulgaris and
some infectious diseases. However, the probability of misclassification within this specific
cohort with an ICD diagnosis of rosacea is likely to be negligible. Lastly, the present Taiwanese
study population mainly consisted of Taiwanese with Han ethnicity and mostly type III/IV
Fitzpatrick skin types.[39] Therefore, caution is advised when attempting to extrapolate our
results to patients of other ethnicities.
In conclusion, the present results indicate that patients with rosacea, particularly those with
moderate-to-severe disease, have an increased risk of CKD that is not completely explained by
traditional risk factors. Future research should attempt to identify the mechanisms underlying
this increase in CKD risk. Patients with rosacea and their physicians should be aware of this
potential link with CKD. Careful monitoring of renal function and avoidance of long-term use
of nephrotoxic drugs should be considered as part of integrated care for patients with rosacea,
particularly those older than 50 years.
Acknowledgments
This study is based in part on data from the National Health Insurance Research Database pro-
vided by the National Health Insurance Administration, Ministry of Health and Welfare and
managed by the National Health Research Institutes. The interpretation and conclusions con-
tained herein do not represent those of the Taiwan National Health Insurance Administration,
Ministry of Health and Welfare or National Health Research Institutes.
Author Contributions
Conceptualization: HYC WYH CHH JJW SJL YWH PJC.
Data curation: HYC WYH CHH JJW YWH PJC.
Formal analysis: HYC CHH SJL YWH PJC.
Funding acquisition: HYC.
Investigation: HYC WYH CHH JJW SJL YWH PJC.
Methodology: HYC WYH CHH JJW SJL YWH PJC.
Project administration: HYC WYH CHH JJW SJL YWH PJC.
Resources: WYH CHH JJW YWH PJC.
Software: WYH CHH JJW YWH PJC.
Supervision: HYC WYH CHH JJW SJL YWH PJC.
Validation: HYC WYH CHH JJW SJL YWH PJC.
CKD risk in patients with rosacea
PLOS ONE | https://doi.org/10.1371/journal.pone.0180446 October 2, 2017 9 / 12
Visualization: HYC WYH CHH JJW SJL YWH PJC.
Writing – original draft: HYC WYH YWH.
Writing – review & editing: CHH JJW SJL PJC.
References
1. Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD, et al. (2011) Clinical, cellular, and
molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 15:2–11. Epub
2011/11/15. https://doi.org/10.1038/jidsymp.2011.7 PMID: 22076321.
2. Spoendlin J, Voegel JJ, Jick SS, Meier CR.(2013) Migraine, triptans, and the risk of developing rosacea:
a population-based study within the United Kingdom. J Am Acad Dermatol 69:399–406. https://doi.org/
10.1016/j.jaad.2013.03.027 PMID: 23643255.
3. Duman N, Ersoy Evans S, Atakan N.(2014) Rosacea and cardiovascular risk factors: a case control
study. J Eur Acad Dermatol Venereol 28:1165–1169. https://doi.org/10.1111/jdv.12234 PMID:
23909954.
4. Hua TC, Chung PI, Chen YJ, Wu LC, Chen YD, Hwang CY, et al.(2015) Cardiovascular comorbidities in
patients with rosacea: A nationwide case-control study from Taiwan. J Am Acad Dermatol 73:249–254.
https://doi.org/10.1016/j.jaad.2015.04.028 PMID: 26004520.
5. Rainer BM, Fischer AH, Luz Felipe da Silva D, Kang S, Chien AL.(2015) Rosacea is associated with
chronic systemic diseases in a skin severity-dependent manner: results of a case-control study. J Am
Acad Dermatol 73:604–608. https://doi.org/10.1016/j.jaad.2015.07.009 PMID: 26256428.
6. Shankar A, Klein R, Klein BE.(2006) The association among smoking, heavy drinking, and chronic kid-
ney disease. Am J Epidemiol 164:263–271. https://doi.org/10.1093/aje/kwj173 PMID: 16775042.
7. Kawaguchi Y, Mine T, Kawana I, Yasuzaki H, Kokuho T, Toya Y, et al.(2009) Gastroesophageal reflux
disease in chronic renal failure patients: evaluation by endoscopic examination. Tokai J Exp Clin Med
34:80–83. PMID: 21319004.
8. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. (2003) Kidney disease
as a risk factor for development of cardiovascular disease: a statement from the American Heart Associ-
ation Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiol-
ogy, and Epidemiology and Prevention. Circulation 108:2154–2169. https://doi.org/10.1161/01.CIR.
0000095676.90936.80 PMID: 14581387.
9. Casas C, Paul C, Lahfa M, Livideanu B, Lejeune O, Alvarez-Georges S, et al. (2012) Quantification of
Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Der-
matol 21:906–910. https://doi.org/10.1111/exd.12030 PMID: 23171449.
10. Bakar O, Demircay Z, Yuksel M, Haklar G, Sanisoglu Y.(2007) The effect of azithromycin on reactive
oxygen species in rosacea. Clin Exp Dermatol 32:197–200. https://doi.org/10.1111/j.1365-2230.2006.
02322.x PMID: 17244346.
11. Zhong S, Sun N, Liu H, Niu Y, Chen C, Wu Y. Topical tranexamic acid improves the permeability barrier
in rosacea.(2015) Dermatologica Sinica 33:112–117. https://doi.org/10.1016/j.dsi.2015.04.012
12. Kang HT, Kim JK, Shim JY, Lee HR, Linton JA, Lee YJ.(2012) Low-grade inflammation, metabolic syn-
drome and the risk of chronic kidney disease: the 2005 Korean National Health and Nutrition Examina-
tion Survey. J Korean Med Sci 27:630–635. https://doi.org/10.3346/jkms.2012.27.6.630 PMID:
22690094.
13. Kaysen GA, Eiserich JP.(2004) The role of oxidative stress-altered lipoprotein structure and function
and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc
Nephrol 15:538–548. PMID: 14978155.
14. Chiu HY, Huang HL, Li CH, Yin YJ, Chen HA, Hsu ST, et al.(2015) Increased risk of glomerulonephritis
and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comor-
bidity: a nationwide population-based cohort study. Br J Dermatol 173:146–154. https://doi.org/10.
1111/bjd.13599 PMID: 25511692.
15. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM.(2013) Risk of moderate to advanced
kidney disease in patients with psoriasis: population based cohort study. BMJ 347:f5961. https://doi.
org/10.1136/bmj.f5961 PMID: 24129480.
16. Chiu HY, Huang HL, Li CH, Chen HA, Yeh CL, Chiu SH, et al. (2015) Increased Risk of Chronic Kidney
Disease in Rheumatoid Arthritis Associated with Cardiovascular Complications—A National Popula-
tion-Based Cohort Study. PLoS One 10:e0136508. https://doi.org/10.1371/journal.pone.
0136508PONE-D-15-23571. PMID: 26406879.
CKD risk in patients with rosacea
PLOS ONE | https://doi.org/10.1371/journal.pone.0180446 October 2, 2017 10 / 12
17. Yamasaki K, Gallo RL.(2009) The molecular pathology of rosacea. J Dermatol Sci. 55:77–81. https://
doi.org/10.1016/j.jdermsci.2009.04.007 PMID: 19481425.
18. Chiu H-Y, Cheng Y-P, Tsai T-F.(2012) T helper type 17 in psoriasis: From basic immunology to clinical
practice. Dermatologica Sinica 30:136–141. https://doi.org/10.1016/j.dsi.2012.08.002
19. Hung SC, Chang YK, Liu JS, Kuo KL, Chen YH, Hsu CC, et al.(2015) Metformin use and mortality in
patients with advanced chronic kidney disease: national, retrospective, observational, cohort study.
Lancet Diabetes Endocrinol. 3:605–614. https://doi.org/10.1016/S2213-8587(15)00123-0 PMID:
26094107.
20. Tseng CW, Lin CL, Chen YT, Jeng LB. (2017) Ischemic Bowel Syndrome in Patients with Spinal Cord
Injury: A Nationwide Study. PLoS One. 12:e0169070. https://doi.org/10.1371/journal.pone.0169070
PMID: 28056095.
21. Akin Belli A, Ozbas Gok S, Akbaba G, Etgu F, Dogan G.(2016) The relationship between rosacea and
insulin resistance and metabolic syndrome. Eur J Dermatol 26:260–264. https://doi.org/10.1684/ejd.
2016.2748 PMID: 27328660.
22. Aldrich N, Gerstenblith M, Fu P, Tuttle MS, Varma P, Gotow E, et al.(2015) Genetic vs Environmental
Factors That Correlate With Rosacea: A Cohort-Based Survey of Twins. JAMA Dermatol 151:1213–
1219. 2429555 https://doi.org/10.1001/jamadermatol.2015.2230 PMID: 26307938.
23. Said S, Hernandez GT.(2014) The link between chronic kidney disease and cardiovascular disease. J
Nephropathol 3:99–104. https://doi.org/10.12860/jnp.2014.19 PMID: 25093157.
24. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al.(2008) All-cause mortality attribut-
able to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet
371:2173–2182. https://doi.org/10.1016/S0140-6736(08)60952-6 PMID: 18586172.
25. Kronbichler A, Mayer G.(2013) Renal involvement in autoimmune connective tissue diseases. BMC
Med 11:95. https://doi.org/10.1186/1741-7015-11-95 PMID: 23557013.
26. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al.(2004) The metabolic syn-
drome and chronic kidney disease in U.S. adults. Ann Intern Med 140:167–174. PMID: 14757614.
27. Carrero JJ, Stenvinkel P. (2009) Persistent inflammation as a catalyst for other risk factors in chronic
kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 4 Suppl 1:S49–55. https://doi.org/10.
2215/CJN.02720409 PMID: 19996005.
28. Arici M, Walls J.(2001) End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-
reactive protein the missing link? Kidney Int 59:407–414. https://doi.org/10.1046/j.1523-1755.2001.
059002407.x PMID: 11168922.
29. Buhl T, Sulk M, Nowak P, Buddenkotte J, McDonald I, Aubert J, et al.(2015) Molecular and Morphologi-
cal Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways. J
Invest Dermatol 135:2198–2208. Epub 2015/04/08. https://doi.org/10.1038/jid.2015.141 PMID:
25848978.
30. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, et al.(2005) IL-10, IL-6,
and TNF-alpha: central factors in the altered cytokine network of uremia—the good, the bad, and the
ugly. Kidney Int 67:1216–1233. https://doi.org/10.1111/j.1523-1755.2005.00200.x PMID: 15780075.
31. Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, et al.(2010) The NLRP3 inflammasome
promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 21:1732–1744. https://doi.org/
10.1681/ASN.2010020143 PMID: 20688930.
32. Granata S, Masola V, Zoratti E, Scupoli MT, Baruzzi A, Messa M, et al.(2015) NLRP3 inflammasome
activation in dialyzed chronic kidney disease patients. PLoS One 10:e0122272. https://doi.org/10.
1371/journal.pone.0122272 PONE-D-14-31723. PMID: 25798846.
33. Tisma VS, Basta-Juzbasic A, Jaganjac M, Brcic L, Dobric I, Lipozencic J, et al.(2009) Oxidative stress
and ferritin expression in the skin of patients with rosacea. J Am Acad Dermatol 60:270–276. https://
doi.org/10.1016/j.jaad.2008.10.014 PMID: 19028405.
34. Oztas MO, Balk M, Ogus E, Bozkurt M, Ogus IH, Ozer N.(2003) The role of free oxygen radicals in the
aetiopathogenesis of rosacea. Clin Exp Dermatol 28:188–192. PMID: 12653711.
35. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC.(2012) Oxidative stress, anti-oxidant thera-
pies and chronic kidney disease. Nephrology 17:311–321. https://doi.org/10.1111/j.1440-1797.2012.
01572.x PMID: 22288610.
36. Egeberg A, Hansen PR, Gislason GH, Thyssen JP.(2016) Assessment of the risk of cardiovascular dis-
ease in patients with rosacea. J Am Acad Dermatol 75:336–339. https://doi.org/10.1016/j.jaad.2016.
02.1158 PMID: 27444070.
37. Egeberg A, Hansen PR, Gislason GH, Thyssen JP.(2016) Patients with Rosacea Have Increased Risk
of Depression and Anxiety Disorders: A Danish Nationwide Cohort Study. Dermatology 232:208–213.
https://doi.org/10.1159/000444082 PMID: 26954304.
CKD risk in patients with rosacea
PLOS ONE | https://doi.org/10.1371/journal.pone.0180446 October 2, 2017 11 / 12
38. Egeberg A, Hansen PR, Gislason GH, Thyssen JP.(2016) Exploring the Association Between Rosacea
and Parkinson Disease: A Danish Nationwide Cohort Study. JAMA Neurol 73:529–534. https://doi.org/
10.1001/jamaneurol.2016.0022 PMID: 26999031.
39. Li YW, Chu CY.(2007) The minimal erythema dose of broadband ultraviolet B in Taiwanese. J Formos
Med Assoc 106:975–978. https://doi.org/10.1016/S0929-6646(08)60071-6 PMID: 18063522.
CKD risk in patients with rosacea
PLOS ONE | https://doi.org/10.1371/journal.pone.0180446 October 2, 2017 12 / 12
